A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
Clinical trial NCT06746870 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06746870
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-01
- Primary completion
- 2025-11-01
- Enrollment
- 148
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.